Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QAX576 in Rapidly Progressive IPF
NCT01266135Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2010
- Primary completion
- Apr 2013
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of dectrekumab in idiopathic pulmonary fibrosis (IPF), sponsored by Novartis. Started Dec 2010; status: terminated.
02
Drugs
dectrekumab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT01266135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01266135.